Keywords: Biomarkers, Cancer, Prostate, Metabolism
Motivation: MRI agents that can monitor abnormal glutamine utilization, a hallmark of many aggressive cancers, are not clinically available.
Goal(s): We investigated the utility of glutamine as a chemical exchange saturation transfer (CEST) agent to evaluate its utilization.
Approach: Phantoms revealed contrast differences between glutamine and its metabolic products. Dynamic CEST images (in vivo) were acquired in 2 prostate cancer xenograft models after intravenous injection of glutamine. MALDI (matrix-assisted laser desorption/ionization) images of the same tumors (ex vivo) were collected for validation.
Results: CEST and MALDI images could distinguish prostate tumors derived from cell lines with known differences in glutamine utilization.
Impact: The potential of CEST (chemical exchange saturation transfer) MRI to evaluate glutamine utilization was evaluated in preclinical prostate cancer models (DU-145 and LNCaP). CEST enhancement images upon infusion of glutamine could distinguish tumors that differed in glutamine utilization.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords